Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Acquisitive Valeant takes first bite at dental market with $312m OraPharma buy

This article was originally published in Scrip

Executive Summary

Valeant Pharmaceuticals International's latest company buy-out sees the acquisitive Canadian firm enter the dental segment of the healthcare market for the first time. Valeant views the dental market as having similar characteristics to speciality markets like dermatology and ophthalmology, in which it already has a presence. It also sees the opportunity for cross-selling some of its current products, such as the cold sore treatment Xerese (aciclovir plus hydrocortisone) that it acquired from Meda last year (scripintelligence.com, 30 June 2011).

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC017768

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel